Main Focus: Gluten and Starch Digestibility
Conditions
Keywords
Gluten, Starch, Digestive enzymes, Probiotics
Brief summary
This is a pilot, feasibility study to evaluate, test and optimize sample analysis procedures and protocols before the full-scale, crossover study is conducted.
Detailed description
Two important factors can influence the proportions of gluten and starch that resist digestion: (1) enzyme availability and specificity and (2) the structural properties of the food. A complete evaluation of gluten digestion and of the impact of dietary supplements is difficult to conduct because it is not easy to obtain samples of digestive chime. The analysis of the ileal effluent of healthy ileostomy patients constitutes a non-invasive alternative to intubation techniques for the study of nutrient digestion and of the fate of probiotics in the small intestine. The main aim of this study is to test and optimize sample analysis protocols before conducting the full-scale, crossover study which will aim at evaluating the impact of two dietary supplements (Glutalytic® and DE111®) and of oatmeal properties on the digestion of gluten and starch and on the glycemic response.
Interventions
Sponsors
Teagasc
Atlantia Food Clinical Trials
Deerland Enzymes
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Subject has given written informed consent * Subject has an ileostomy stable for at least 3 months post-operative and shows normal stoma functions * Subject is otherwise healthy * Subject is available to participate in the study sessions on the proposed dates
Exclusion criteria
* Subject has coeliac disease or allergy to wheat products and/or any other ingredients in the test meal and standard meals * Case of obstruction of the stoma in the past 3 months * Body mass index \< 18 kg/m2 or \> 30 kg/m2. * Diagnosed mouth, throat or active gastrointestinal pathology (other than ileostomy) that may affect normal ingestion and digestion of food. * History of pancreatic disease * Subject is immunocompromised (HIV positive, transplant patient, on antirejection medications, on a steroid for \>30 days, or chemotherapy or radiotherapy within the last year) * Subject has Type 1 or Type 2 diabetes mellitus. * Subject has a history of bariatric surgery. * Subject has a history of drug and/or alcohol abuse at the time of enrolment * Subject is currently participating in another study, or plans to participate in another study during the study period * Women of child-bearing potential who do not use an acceptable method of contraception * Pregnant or nursing (lactating) women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Undigested wheat protein after each treatment | 9-hour period after the test meal | Difference between the mean concentration of undigested wheat protein in ileal effluent samples. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Vegetative DE111 cells | 9-hour period after the test meal | Mean concentration of DE111® cells recovered in the ileal effluent samples. |
| Glycemic response | At baseline, and at different time-points in the 9-hour period after consumption of the test meal. | Difference between the mean area under the glucose concentration (measured in the interstitial fluid) curves following each treatment. |
| Undigested starch | 9-hour period after the test meal | Difference between the mean concentration of undigested starch in ileal effluent samples. |
| Undigested food particles | 9-hour period after the test meal | Pictures of undigested foods particles and microscopy will be combined for a combined assessment of macro- and micro- structural characteristics of the food particles recovered in ileal effluent samples. |
Countries
Ireland
Outcome results
None listed